KOREA WHO

Lee Dong-hoon is the President and CEO of SK Biopharmaceuticals. He also serves as CEO of its subsidiaries, SK Life Science and SK Life Science Labs.

He is committed to expanding sales of the company’s novel epilepsy treatment, Cenobamate, while actively pursuing the discovery of new drug candidates.

Lee was born on August 12, 1968.

He studied Business Administration at Seoul National University and completed his MBA at the Fisher College of Business, Ohio State University, in the United States.

Beginning his career as a certified public accountant, Lee led the investment advisory division at KPMG Samjong before entering the pharmaceutical industry as Head of Business Development at Dong-A Pharmaceutical. He later joined Dong-A Socio Holdings, where he played a key role in transitioning the company into a holding company structure and was appointed Executive Vice President and CEO in 2013. He also served as Executive Vice President in charge of global business at Dong-A ST.

In 2019, Lee joined SK Group as Head of the Investment Center, overseeing investments and mergers and acquisitions in the biopharmaceutical sector. He was appointed President of SK Biopharmaceuticals in 2022.

He was involved in establishing a joint venture with U.S.-based Roivant, as well as in investments in cell and gene therapy CDMO companies Yposkesi and CBM.

With his background as an investment expert, Lee has brought a dual advantage to the pharmaceutical and biotech industries.

He is also focusing on expanding SK Biopharmaceuticals’ digital healthcare business.

#LeeDonghoon #SKBiopharmaceuticals #Cenobamate #SKLifeScience #biotechleadership #CDMO #Roivant #Yposkesi #digitalhealthcare #biopharmainvestment